Skip to main content
PharmaCielo Ltd. logo

PharmaCielo Ltd. — Investor Relations & Filings

Ticker · PCLO ISIN · CA71716K1012 LEI · 5493002XOFWMT83TYQ57 TSXV Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2021-08-20 Regulatory Filings
Country CA Canada
Listing TSXV PCLO

About PharmaCielo Ltd.

https://www.pharmacielo.com/

PharmaCielo Ltd. is a global supplier specializing in the cultivation, processing, and distribution of medicinal-grade cannabis extracts and dried flower. The company focuses on ethical and sustainable production, aiming to be a leading partner in the global medicinal cannabis market. Utilizing ideal equatorial conditions, PharmaCielo operates large-scale, high-efficiency production facilities, including 12 hectares of open-air greenhouses, enabling four full crops annually for reliable supply. Its product portfolio includes standardized extracts, such as high-purity CBD Isolate, and both psychoactive and non-psychoactive derivatives. Production adheres to pharmaceutical-quality standards, supported by proprietary genetics maintained in a tissue culture lab and advanced processing facilities ensuring consistency and safety.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. It is a certification letter rather than the interim report itself. The document is only 3012 characters long and primarily contains officer certification statements without substantive financial data or analysis. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself.
2021-08-20 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for the three and six months ended June 30, 2021, and is unaudited. It contains detailed financial statements including statements of financial position, loss and comprehensive loss, changes in shareholders' equity, cash flows, and accompanying notes. The presence of actual financial data and analysis for a period shorter than a full fiscal year (quarterly or half-year) indicates this is an interim or quarterly report. The document is not a full annual report, audit report, or earnings release, but a comprehensive interim financial report. Therefore, the appropriate classification is 'Interim / Quarterly Report' (IR). H1 2021
2021-08-20 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management's Discussion and Analysis' (MD&A) for the three and six months ended June 30, 2021, dated August 19, 2021. It includes detailed discussion of financial condition, operating performance, recent developments, COVID-19 impact, and company overview. The MD&A is prepared in accordance with Canadian securities regulations (NI 51-102) and accompanies unaudited condensed interim consolidated financial statements. The document length is about 15,000 characters, indicating a substantive report rather than a brief announcement. The content and timing correspond to a quarterly or interim report rather than a full annual report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR), which includes comprehensive financial reports for periods shorter than a full fiscal year with substantive financial data and analysis. H1 2021
2021-08-20 English
News release - English.pdf
Regulatory Filings
2021-08-04 English
News release - English.pdf
Regulatory Filings
2021-07-26 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing PharmaCielo's CEO participation in an upcoming cannabis forum event. It contains no financial statements, no detailed financial data, no regulatory filings, no voting results, no management or board changes, no capital or financing updates, and no legal proceedings. It is a general corporate announcement about an investor event participation. The document length is 5785 characters, but the content is clearly an announcement rather than a report or transcript. Therefore, it does not fit into any specific financial report category. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2021-06-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.